A cost variation analysis of chronic obstructive pulmonary disorder medications in the Indian market concerning Jan Aushadhi medications and their branded counterparts
Open Access
- 30 April 2025
- journal article
- Published by Medip Academy in International Journal Of Community Medicine And Public Health
- Vol. 12 (5) , 2393-2399
Abstract
Medications and pharmaceutical expenses constitute a significant portion of out-of-pocket health expenditures for households in India, posing a substantial financial burden. The objective of this study was to assess the cost differences among drugs utilized in the treatment of chronic obstructive pulmonary disorder (COPD), specifically comparing those available at Jan Aushadhi pharmacies with various branded drug formulations. In the study, we calculated the cost differences (in Indian Rupees), cost ratios, and cost variations by contrasting the cost of generic Jan Aushadhi medications with the most expensive and least expensive branded medications in the same category. Our study revealed that the price of branded drugs prescribed for obstructive pulmonary conditions was higher than that of generic drugs purchased from Jan Aushadhi pharmacies except in the case of doxophylline 400 mg tablet. The highest cost difference was observed in the combination drug of formoterol 6 mcg + fluticasone propionate 250 mcg inhaler (740 and 290). Cost variance and cost ratio were highest in salbutamol 4 mg tablets (2386%) and (24.86) respectively. Findings indicate that across all classes of drugs investigated, the costs associated with generic drugs in Jan Aushadhi centers were markedly lower than those associated with branded drugs. Medications offered by Jan Aushadhi pharmacies are more cost-effective than their branded equivalents, rendering COPD treatment more accessible and affordable for individuals with limited financial means.Keywords
This publication has 14 references indexed in Scilit:
- Association of Exposure to Biomass Fuels with Occurrence of Chronic Obstructive Pulmonary Disease in Rural Western China: A Real-World Nested Case-Control StudyInternational Journal of Chronic Obstructive Pulmonary Disease, 2023
- A cost analysis and availability scenario of drugs and oral care products prescribed for common oral conditions with reference to the current Indian market prices, Jan Aushadhi, and the state medical commissionsJournal of Family Medicine and Primary Care, 2022
- Prevalence of chronic obstructive pulmonary disease in India: A systematic review and meta-analysisLung India, 2021
- Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claimsPLOS Medicine, 2019
- Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994–2014BMJ Open, 2018
- The unmet global burden of COPDGlobal Health, Epidemiology and Genomics, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- A Cost Analysis of the Jan Aushadhi Scheme in IndiaInternational Journal of Health Policy and Management, 2017
- Chronic Obstructive Pulmonary Disease and its Non-Smoking Risk Factors in IndiaCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2015
- Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendationsLung India, 2013